Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKB410 in Advanced Solid Tumors
NCT05906537Phase 1Completed
- Sponsor
- Kelun-Biotech
- Start
- Jul 2023
- Primary completion
- Mar 2026
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MK-3120 in solid tumor, sponsored by Kelun-Biotech. Primary endpoints: Dose-limiting toxicity at 28 days and Maximum Tolerated Dose at 28 days. Started Jul 2023; status: completed.
02
Drugs
MK-3120
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05906537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05906537.